ADAPTIMMUNE Trademark

Trademark Overview


On Wednesday, March 31, 2021, a trademark application was filed for ADAPTIMMUNE with the United States Patent and Trademark Office. The USPTO has given the ADAPTIMMUNE trademark a serial number of 79312975. The federal status of this trademark filing is REGISTERED as of Tuesday, January 25, 2022. This trademark is owned by Adaptimmune Limited. The ADAPTIMMUNE trademark is filed in the Pharmaceutical Products and Medical & Beauty Services & Agricultural Services categories with the following description:

Pharmaceutical preparations for the treatment of cancer and autoimmune diseases; pharmaceutical immunotherapy preparations for use in cancer treatment; T-cell receptors , namely, pharmaceutical preparations for use in cancer treatment; pharmaceutical immunotherapy preparations comprising engineered T-cell receptors for use in cancer treatment; pharmaceutical immunotherapy preparations comprising genes encoding engineered T-cell receptors for use in cancer treatment

Medical treatment services; medical immunotherapy services; medical treatment services and medical treatment services for immune-therapy comprising harvesting a patient's white blood cells, combining white blood cells with an engineered T-cell receptor therapeutic, transducing the white blood cells with the gene encoding the engineered T-cell receptor and infusion of the transduced white blood cells back into the patient
adaptimmune

General Information


Serial Number79312975
Word MarkADAPTIMMUNE
Filing DateWednesday, March 31, 2021
Status700 - REGISTERED
Status DateTuesday, January 25, 2022
Registration Number6624493
Registration DateTuesday, January 25, 2022
Mark Drawing3000 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, November 9, 2021

Trademark Statements


Description of MarkThe mark consists of a stylized circular design consisting of several curved parallel lines to the left of the stylized wording "ADAPTIMMUNE".
Goods and ServicesPharmaceutical preparations for the treatment of cancer and autoimmune diseases; pharmaceutical immunotherapy preparations for use in cancer treatment; T-cell receptors , namely, pharmaceutical preparations for use in cancer treatment; pharmaceutical immunotherapy preparations comprising engineered T-cell receptors for use in cancer treatment; pharmaceutical immunotherapy preparations comprising genes encoding engineered T-cell receptors for use in cancer treatment
Pseudo MarkADAPT IMMUNE
Goods and ServicesMedical treatment services; medical immunotherapy services; medical treatment services and medical treatment services for immune-therapy comprising harvesting a patient's white blood cells, combining white blood cells with an engineered T-cell receptor therapeutic, transducing the white blood cells with the gene encoding the engineered T-cell receptor and infusion of the transduced white blood cells back into the patient

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateSaturday, June 12, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateSaturday, June 12, 2021
Primary Code044
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAdaptimmune Limited
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressGB

Party NameAdaptimmune Limited
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressGB

Party NameAdaptimmune Limited
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressGB

Trademark Events


Event DateEvent Description
Monday, August 1, 2022FINAL DECISION TRANSACTION PROCESSED BY IB
Friday, July 8, 2022FINAL DISPOSITION NOTICE SENT TO IB
Friday, July 8, 2022FINAL DISPOSITION PROCESSED
Monday, April 25, 2022FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Tuesday, January 25, 2022REGISTERED-PRINCIPAL REGISTER
Tuesday, November 9, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, November 9, 2021PUBLISHED FOR OPPOSITION
Wednesday, October 20, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, October 7, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, September 13, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, September 13, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, September 13, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sunday, August 15, 2021REFUSAL PROCESSED BY IB
Tuesday, July 27, 2021NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Tuesday, July 27, 2021REFUSAL PROCESSED BY MPU
Saturday, July 17, 2021NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Friday, July 16, 2021NON-FINAL ACTION WRITTEN
Friday, July 16, 2021ASSIGNED TO EXAMINER
Wednesday, June 16, 2021APPLICATION FILING RECEIPT MAILED
Saturday, June 12, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Thursday, June 10, 2021SN ASSIGNED FOR SECT 66A APPL FROM IB